Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate

Area of Science:

• Polymer chemistry
• Nanomedicine
• Cancer biology

Background:

• Prostate cancer bone metastasis presents a significant clinical challenge.
• Combination therapy offers a promising strategy for enhanced anticancer efficacy.
• Targeted drug delivery systems can improve therapeutic outcomes and reduce systemic toxicity.

Purpose of the Study:

• To develop and evaluate a novel polymer nanoconjugate for combined anticancer and antiangiogenic therapy.
• To assess the efficacy of the nanoconjugate against prostate carcinoma cells.
• To investigate the nanoconjugate's effect on endothelial cell proliferation, migration, and tube formation.

Main Methods:

• Synthesis of an N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer nanoconjugate.
• Incorporation of the bisphosphonate alendronate for bone targeting.
• Conjugation of the cathepsin B-cleavable chemotherapy agent paclitaxel (PTX).
• In vitro evaluation of cytotoxicity against prostate cancer cells and antiangiogenic effects on endothelial cells.

Main Results:

• The nanoconjugate demonstrated significant inhibition of prostate carcinoma cell proliferation.
• The polymer therapeutic effectively suppressed endothelial cell proliferation, migration, and tube formation.
• Alendronate facilitated bone targeting, while PTX provided the cytotoxic effect.

Conclusions:

• The developed polymer nanoconjugate shows potential as a dual-action therapeutic for prostate cancer.
• This approach combines targeted delivery, anticancer activity, and antiangiogenic effects.
• Further investigation is warranted for in vivo efficacy and clinical translation.